🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Clinical Trials in Egypt / NCT07423663
Active, not recruiting Phase EARLY_PHASE1

Antimicrobial Effect of Calcium Silicate and Pectin as Intracanal Medications in Necrotic Teeth With Periapical Lesions

NCT07423663 · tracked via the Priya Life Science Egypt tracker
Phase
Phase EARLY_PHASE1
Started
2024-09-01
Last updated
2026-02-20

Condition(s) studied

Asymptomatic Apical Periodontitis

Investigational drug(s) / intervention(s)

Calcium Hydroxide Intracanal medication →Calcium silicate based intracanal medicationPectin

Calcium Hydroxide Intracanal medication: Patients receiving CaOH (Metapaste) intracanal medication

Calcium silicate based intracanal medication: Patients receiving Calcium silicate based (Bio-C Temp) intracanal medication

Pectin: Patients receiving Pectin intracanal medication

Study summary

It is tackling antimicrobial resistance in endodontics, specifically comparing different intracanal medications used in root canal treatment. Given the growing concern over resistant bacterial strains, our study aims to evaluate the effectiveness of various medicaments in eliminating endodontic pathogens while minimising the risk of resistance development. By integrating microbiological analysis and clinical relevance, our research seeks to provide evidence-based recommendations for optimising intracanal disinfection protocols and improving treatment outcomes in endodontic infections.

Eligibility

Sex
ALL
Min age
21 Years
Max age
49 Years
Healthy volunteers
Accepted
Inclusion Criteria * Patients presenting with a single rooted mandibular premolar tooth with a closed apex and a single patent canal type I in Vertucci's classification (Vertucci et al., 1974). * Having a necrotic pulp. * A pocket depth measurement of \< 3 mm. * Teeth with no previous history of endodontic treatment. * Teeth with periapical lesions of endodontic origin having a periapical index score of 4 or 5 (Orstavik et al., 1986) * Patients who took antibiotics within the period of three months before the study. * Non-restorable teeth. * Teeth with periodontal pockets deeper than 4mm, with or without concomitant or combined endo-perio communication * Multirooted teeth. * Previously initiated or treated teeth. * Teeth with root canal calcifications or resorption. * Teeth with internal/external root resorption or root fracture. * Immune-compromised patients or patients with systemic diseases i.e. (diabetes mellitus, human immunodeficiency virus, leukemia, neutropenia, undergoing chemo- or systemic corticosteroid therapy) * Teeth with root curvature of more than 15 degrees. * Pregnant women * Patients with known sensitivity to the medicaments used in this study.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Suez Canal University Ismailia Ismailia Governorate

More Suez Canal University trials in Egypt

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07423663 on ClinicalTrials.gov ↗ ← All trials in Egypt